XORTX Therapeutics (XRTX) Share-based Compensation (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Share-based Compensation came in at $7816.0 in Q1 2026, down 12.86% YoY from $8969.0 in Q1 2025, and up 89.52% on a QoQ basis from $4124.0 in Q4 2025.
XORTX Therapeutics (XRTX) Share-based Compensation (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Share-based Compensation data on file, last reported at $7816.0 in Q1 2026.
- Quarterly Share-based Compensation fell 12.86% year-over-year to $7816.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24002.0 (down 69.37% YoY) and the FY2025 annual result came in at $25155.0, down 79.47% from the prior year.
- Share-based Compensation grew to $7816.0 in Q1 2026, from $4124.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $333311.8 in Q2 2022 to a low of $4124.0 in Q4 2025.
- A 5-year average of $45178.3 and a median of $21850.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 352.97% — and 2023, when it sank 90.77%.
- Tracing XRTX's Share-based Compensation over 5 years: stood at $70905.4 in 2022, then tumbled by 59.36% to $28815.0 in 2023, then sank by 67.01% to $9505.0 in 2024, then tumbled by 56.61% to $4124.0 in 2025, then jumped by 89.52% to $7816.0 in 2026.
- The last three Share-based Compensation figures came in at $7816.0 (Q1 2026), $4124.0 (Q4 2025), and $5117.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | XORTX Therapeutics | 2.78 Mn | 2.78 Mn | - | 7,816.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,816.00 |
| Mar 31, 2026 | 7,816.00 |
| Dec 31, 2025 | 4,124.00 |
| Dec 31, 2025 | 4,124.00 |
| Sep 30, 2025 | 5,117.00 |
| Sep 30, 2025 | 5,117.00 |
| Jun 30, 2025 | 6,945.00 |
| Jun 30, 2025 | 6,945.00 |
| Mar 31, 2025 | 8,969.00 |
| Mar 31, 2025 | 8,969.00 |
| Dec 31, 2024 | 9,505.00 |
| Dec 31, 2024 | 9,505.00 |
| Sep 30, 2024 | 15,857.00 |
| Sep 30, 2024 | 15,857.00 |
| Jun 30, 2024 | 44,031.00 |
| Jun 30, 2024 | 44,031.00 |
| Mar 31, 2024 | 53,134.00 |
| Mar 31, 2024 | 53,134.00 |
| Dec 31, 2023 | 28,815.00 |
| Dec 31, 2023 | 28,815.00 |